# CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)

> **NCT04021082** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **Portola Pharmaceuticals**

## Conditions studied

- Peripheral T-Cell Lymphoma (PTCL NOS)
- Nodal Lymphomas of T Follicular Helper (TFH)
- Follicular T-cell Lymphoma (FTCL)
- AITL
- ALCL
- HSTCL
- EATL I,II
- MEITL, EATL Type II
- Nasal Lymphoma

## Interventions

- **DRUG:** Cerdulatinib

## Key facts

- **NCT ID:** NCT04021082
- **Lead sponsor:** Portola Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-11-15
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-06-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor decision to not initiate the trial
- **Last updated:** 2023-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04021082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04021082, "CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT04021082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*